- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03794765
Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis (AAASUC)
Use of Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis: A Randomised Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
All patients with active ulcerative colitis who present to the Outpatient department or the emergency services of PGIMER shall be screened. Those patients who have acute severe ulcerative colitis shall be assessed for inclusion into the study. Patients who fulfil the eligibility criteria will be randomised into two groups.
Group A will include patients in the intervention arm. They will be given intravenous antibiotics for three days. Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallized powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly. Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day, after intradermal testing for hypersensitivity. Both the drugs will be given for five days. In addition, they will receive the standard of care mentioned below.
Group B will include patients from the placebo arm. They will be given the standard of care as mentioned below. In addition, they will be infused 0.9 % saline of similar quantity, colour, and from similarly shaped bottles, for three days after sensitivity testing with the saline.
Detailed history and examination shall be done for all the patients. History regarding the stool output, any systemic symptoms, prior treatment history and history regarding any precipitant for the acute episode shall be taken. Examination will include vitals (pulse rate, blood pressure, temperature), general physical examination as well as an abdominal examination. All patients will undergo blood investigations on all three days. This includes a complete blood counts, kidney function tests, serum electrolytes, albumin, C-reactive protein, osteopontin, blood culture. Stool routine microscopic examination, fecal calprotectin, stool assay for clostridium difficile toxin will be done. X ray abdomen will be done on all three days to monitor the diameter of transverse colon. Patients will undergo an unprepared sigmoidoscopy with minimal air insufflation and mucosal biopsy. Biopsies will be taken for histological examination. Procalcitonin, fecal calprotectin and CRP shall be repeated on day 3 of admission.
All patients will be prescribed the standard treatment for acute severe colitis, which includes intravenous steroids (Inj Hydrocortisone 100 mg IV QID or Inj Methyprednisolone 60 mg iv OD), anticoagulation, (Inj Unfractionated heparin 5000 IU S/C BD), intravenous fluid supplementation and correction of electrolytes. Patients will be allowed orally and will be prescribed a diet of 25-30 kcal /kg/day.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chandigarh, India, 160012
- Postgraduate Institute of Medical Education and Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute severe ulcerative colitis as described in European Crohn's and Colitis Organisation (ECCO) guidelines (adapted from Truelove and Witts)
Exclusion Criteria:
- Patients who deny consent
- Age<=12 years
- Pregnant or lactating women
- Severe uncontrolled comorbidities like diabetes mellitus, hypertension, coronary artery disease, chronic liver disease, chronic kidney disease, etc
- History of antibiotic use in the past one month, excluding those who may have received a single dose of antibiotic in past 24 hrs
- History of hypersensitivity or contraindication to steroids or the test drugs
- Presence of toxic megacolon as defined by transverse colon diameter more than 5.5cm on abdominal X-ray
- Patients with evidence of sepsis or active infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Antibiotic
Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
|
Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline.
This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity.
Inj ceftriaxone 1gm IV will be given twelve hourly.
Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml.
It will be infused slowly over thirty minutes, three times per day
|
Placebo Comparator: Placebo
Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
|
Similar placebo infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response as defined by the Oxford's criteria
Time Frame: 48 hours
|
Patients will be defined as complete responders, partial responders or non-responders
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion needing second line therapy
Time Frame: 28 days
|
Second line therapy : Intravenous Infliximab, Intravenous cyclosporine or others
|
28 days
|
Proportion needing colectomy
Time Frame: 28 days
|
Number of patients in each group needing colectomy
|
28 days
|
Mortality
Time Frame: 28 days
|
Number of patients in having mortality
|
28 days
|
Duration of hospital stay
Time Frame: 28 days
|
Length of hospital stay in each group
|
28 days
|
Change in serum CRP levels
Time Frame: 48 hours
|
48 hours
|
|
Change in Mayo disease severity index
Time Frame: 48 hours
|
48 hours
|
|
Patients with Reduction in fecal calprotectin by >100 mcg/mg
Time Frame: 48 hours
|
Number of patients in each group having the predefined decline in fecal calprotectin
|
48 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vishal Sharma, Postgraduate Institute of Medical Education and Research
- Principal Investigator: Shubhra Mishra, Postgraduate Institute of Medical Education and Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NK/5147/DM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Ceftriaxone
-
Baxter Healthcare CorporationHalozyme TherapeuticsCompleted
-
National Institute of Neurological Disorders and...CompletedLyme Disease | Lyme NeuroborreliosisUnited States
-
Yale UniversityStanley Medical Research InstituteTerminated
-
Association Pour La Promotion A Tours De La Reanimation...UnknownSepsis | Septic Shock | Severe SepsisFrance
-
University Medical Centre LjubljanaUnknown
-
Nantes University HospitalCompletedMeningitis | Neurological InfectionsFrance
-
Makerere UniversityCompleted
-
Fundación Pública Andaluza para la gestión de la...CompletedInfectious EndocarditisSpain
-
The Grant Medical College & Sir J.J. Group of HospitalsRecruitingSurgical Wound Infection | Surgical Site InfectionIndia
-
University of RochesterCompleted